Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | LTK | P29376 | 1/20 | 0.34 |
| ▸ | GRK5 | P34947 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8764071 | 0.85 | KCNK3 (0.44) | MRGPRX4KCNK3KCNK9RXRARXRB | |
| SCHEMBL6630905 | 0.83 | NFE2L2 (0.42) | NFE2L2SLC22A12KMT2AGAAATM | |
| SCHEMBL28960868 | 0.81 | KCNN4 (0.36) | PIM1NFE2L2CHEK1AURKADAPK3 | |
| SCHEMBL28960871 | 0.80 | BACE1 (0.41) | PIM1CHEK1AURKADAPK3JAK2 | |
| SCHEMBL29431092 | 0.80 | SLC22A12 (0.36) | NFE2L2MRGPRX4SLC22A12KCNK3KCNK9 | |
| SCHEMBL4394385 | 0.80 | SLC22A12 (0.36) | NFE2L2MRGPRX4SLC22A12KCNK3KCNK9 | |
| SCHEMBL31037153 | 0.79 | SLC22A12 (0.35) | NFE2L2MRGPRX4SLC22A12RXRARXRB | |
| SCHEMBL17201326 | 0.77 | MRGPRX4 (0.49) | PIM1PIM2PTPN1MRGPRX4CCR4 | |
| SCHEMBL2317520 | 0.76 | RXRA (0.46) | PIM1PIM2MRGPRX4RXRARXRB | |
| SCHEMBL9069065 | 0.76 | TRPV4 (0.41) | SLC22A12KMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1290001-B1 | PROCESS FOR THE SELECTIVE DEPROTONATION AND FUNCTIONALIZATION OF 3-SUBSTITUTED BENZOTRIFLUORIDES | DOW AGROSCIENCES LLC (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1290001-A1 | PROCESS FOR THE SELECTIVE DEPROTONATION AND FUNCTIONALIZATION OF 3-SUBSTITUTED BENZOTRIFLUORIDES | Dow AgroSciences LLC (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6462240-B2 | FROMING 2-LITHIOBENZOTRIFLORIDE FROM BENZOTRIFLUORIDE AND ALKYLLITHIUM | DOW AGROSCIENCES LLC | 2002-10-08 | — | — | US | disclosed |
| US-20020010375-A1 | Process for the selective deprotonation and functionalization of 3-substituted benzotrifluorides | CORTEVA AGRISCIENCE LLC | 2002-01-24 | — | — | US | disclosed |
| WO-2001096348-A1 | PROCESS FOR THE SELECTIVE DEPROTONATION AND FUNCTIONALIZATION OF 3-SUBSTITUTED BENZOTRIFLUORIDES | DOW AGROSCIENCES LLC (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010375-A1 | Process for the selective deprotonation and functionalization of 3-substituted benzotrifluorides | BPTF, FGFR2, FGFR4 | PIM1 3454/4885PIM2 1943/4885NFE2L2 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.